Working Group 3-Pathophysiological roles of ALDO/MR in cardiovascular diseases
Key outcomes will be to better understand the consequences of MR activation in the cardiovascular system and their therapeutic and clinical implications, as well as the underlying mechanism of MR activation in the CV system.
The WG3 will study the pathological consequences of the activation and the modulation of the Aldo/MR system on the function and structure in the cardiovascular system, with a special focus on its participation in the development of complications of different cardiovascular risk factors. Such risk factors include hypertension, obesity, atherosclerosis, ageing and heart failure. WG3 will combine complementary and synergistic expertise of partners who have made major contributions to the understanding of Aldosterone action and MR activation in cardiovascular pathophysiology.
The main objectives of the WG3 will be the following:
- To investigate the potential mechanisms and the consequences of Aldo/MR activation in conditions leading to endothelial dysfunction, vascular inflammation and remodeling/calcification in the context of hypertension, atherosclerosis, obesity, heart or renal failure.
- To define the electrophysiological impact of MR activation in cardiomyocytes and its consequences for arrhythmia generation
- To analyze the mechanisms by which the Aldo/MR system influences vascular stiffening and hypercoagulable phenotypes in arterial ageing, hypertension, and heart failure.
- To identify new biotargets involved in Aldo/MR-induced cardiovascular remodeling associated with hypertension, obesity and heart failure development. These newly identified Aldo/MR targets could be additional therapeutic targets to modulate Aldo/MR effects in cardiovascular remodeling.
- To examine the implication of Aldo/MR system in the regulation of the coronary reserve and its impact on myocardial infarct
- To explore the role of inflammation in the cardiovascular consequences of MR activation.
Working Group 3 members
Natalia López Andrés, Spain. WG Leader
Rhian Touyz, UK
Kristina Kusche-Vihrog, Germany
Tilman Volk, Germany
Victoria Cachofeiro, Spain
Ana Briones, Spain
Antoine Ouvrard-Pascaud, France
Frederic Jaisser, France
Jean-Pierre Benitah, France
Patrick Lacolley, France
Luis Michea, Chile
Stefan Chłopicki, Poland
Konstantinos Kallaras, Greece
Aristeidis Kritis, Greece
Michael Wagner, Germany
Research Group 1
Head: Dr Natalia López-Andrés, Head, Cardiovascular Translational Research group and WG3 Leader
Navarrabiomed, Miguel Servet Foundation.
Complejo Hospitalario de Navarra, Pamplona, Spain
Keywords: Aldosterone damage, myocardium, cardiac valves, biomarkers Galectin-3 & ST-2.
Research Group 2
Universidad Autónoma de Madrid group. Spain
Keywords: Cardiovascular pathologies,role of renin-angiotensin-aldosterone system,oxidative stress, COX-2
Research Group 3
Head of Department, Integrative Physiology and Pathophysiology,Cordeliers Research Centre, INSERM
Keywords: Mineralocorticoid receptor, angiotensin II,novel target tissues, Neutrophil Gelatinase-Associated Lipocalin (NGAL)
Research Group 4
Head, Department of Experimental Pharmacology, Jagiellonian Centre for Experimental Therapeutics,
Jagiellion University, Kracow, Poland
Keywords: Endothelial dysfunction and targeted therapy, cardiovascular, new targets for liver steatosis,
Secondary WG: WG5
Research Group 5
Faculty of Medicine, University of Chile
Keywords: Hypertension, kidney damage, inflammation in chronic kidney disease
Research Group 6:
Universidad Complutense, Physiology and Internal Medicine Departments
School of Medicine, Madrid ,Spain
Keywords: Cardiovascular disease, obesity, diabetes, aldosterone
Research Group 7:
Keywords: Epithelial Sodium Channle (ENaC), Epithelial cell plasticity